{
  "id": "3623ddde415a510e",
  "title": "ASH 2025 | Ascentage Pharma Presents Encouraging Data from Phase Ib / II Study of Bcl - 2 Inhibitor Lisaftoclax in Venetoclax - Exposed Patients with Myeloid Malignances",
  "description": "20251208T033000Z",
  "content": "",
  "source": "manilatimes.net",
  "source_url": "https://www.manilatimes.net/2025/12/08/tmt-newswire/globenewswire/ash-2025-ascentage-pharma-presents-encouraging-data-from-phase-ibii-study-of-bcl-2-inhibitor-lisaftoclax-in-venetoclax-exposed-patients-with-myeloid-malignances/2238577",
  "published_at": "20251208T033000Z",
  "fetched_at": "2025-12-09T00:22:19.510482+00:00",
  "category": "health_biotech",
  "subcategory": null,
  "keywords": [
    "aging"
  ],
  "location": "Philippines",
  "raw_data": {
    "url": "https://www.manilatimes.net/2025/12/08/tmt-newswire/globenewswire/ash-2025-ascentage-pharma-presents-encouraging-data-from-phase-ibii-study-of-bcl-2-inhibitor-lisaftoclax-in-venetoclax-exposed-patients-with-myeloid-malignances/2238577",
    "url_mobile": "https://www.manilatimes.net/2025/12/08/tmt-newswire/globenewswire/ash-2025-ascentage-pharma-presents-encouraging-data-from-phase-ibii-study-of-bcl-2-inhibitor-lisaftoclax-in-venetoclax-exposed-patients-with-myeloid-malignances/2238577/amp",
    "title": "ASH 2025 | Ascentage Pharma Presents Encouraging Data from Phase Ib / II Study of Bcl - 2 Inhibitor Lisaftoclax in Venetoclax - Exposed Patients with Myeloid Malignances",
    "seendate": "20251208T033000Z",
    "socialimage": "https://www.manilatimes.net/manilatimes/uploads/images/2025/12/08/857779.png",
    "domain": "manilatimes.net",
    "language": "English",
    "sourcecountry": "Philippines"
  }
}